Rituximab治疗复发淋巴瘤临床研究进展PPT学习教案_第1页
Rituximab治疗复发淋巴瘤临床研究进展PPT学习教案_第2页
Rituximab治疗复发淋巴瘤临床研究进展PPT学习教案_第3页
Rituximab治疗复发淋巴瘤临床研究进展PPT学习教案_第4页
Rituximab治疗复发淋巴瘤临床研究进展PPT学习教案_第5页
已阅读5页,还剩59页未读, 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、会计学1Rituximab治疗复发淋巴瘤临床研究进展治疗复发淋巴瘤临床研究进展 常常 规规 化化 疗疗 +/-RT 造血干细胞造血干细胞移移 植植单克隆单克隆抗体抗体,RIT干扰素新治疗方法新治疗方法烷化剂,蒽环类,烷化剂,蒽环类,FLUVP-16,DDP,Taxanes美 罗 华第1页/共64页 复发难治淋巴瘤复发难治淋巴瘤临床研究临床研究其他治疗其他治疗第2页/共64页第3页/共64页第4页/共64页第5页/共64页方案疾病患者数量ORR/CRASCT performedSurvival in ASCT R-ICEDLBCL3678%/53%70%67% OS at 2 yearsR-IC

2、EAggressive B NHL875%/ 50%100%R-various (mostly ICE) DLBCL59 Not given100%81% OS at 2 yearsR-ICEAggressiveR-DHAPAggressive B NHL5362%/32%38%Median 20.4 months OSDHAP/VIM/DHAP RAggressive B NHL22575%/46% versus63% versusAt 2 years FFS54%/35% R, 46% R, 50%versus 24% respectively respectively in favour

3、 of R (p.001)R-ESHAPDLBCL/MCL/HD24 (15 =Not given79%DFS = 53% DLBCL)R-ESHAPDLBCL/MCL6100%/67%Not doneR-ESHAPAggressive B NHL2692 %/46%88%R-ESHAPAggressive B NHL1856%/28%38%R-ICE or R-DHAPDLBCL1060%/10%Not doneR-ASHAPAggressive B NHL2075%/45%25%R-DHAOXNHL33 (10 were 70%/27%Not stated HIV+)R-ICE or R-

4、DHAPRelapsed DLBCL 39663%/38%52% (n= 204)49% OS at 3 yearsfollowed by HDT(BEAM) and ASCT R maintenance第6页/共64页第7页/共64页R-DHAPDHAPP valueCR+PR75%54%P=0.01FFS50%24%P 0.001PFS52%31%P = 12 monthsFailure from diagnosis 12 monthsFailure from diagnosis = 12 monthsStandard salvage regimen does not overcome p

5、oor prognosis of early relapse第18页/共64页Salvage with rituximab (n=22)Salvage without rituximab (n=87)Salvage with rituximab (n=9)Salvage without rituximab (n=64)Feugier, P. et al. J Clin Oncol; 23:4117-4126 2005Effect of rituximab-containing chemotherapy as salvage treatment at time of first progress

6、ion on overallsurvival after progression: (A) in patients previously treated with cyclophosphamide, doxorubicin,vincristine, and prednisone (CHOP; log-rank test, P = .00043); (B) in patients previously treated withrituximab plus CHOP (log-rank test, P = .076)JOURNAL OF CLINICAL ONCOLOGYCumulative Pr

7、oportion SurvivingCumulative Proportion Survivingwith rituximab Without rituximab with rituximab Without rituximab 第19页/共64页RegimenDisease statusnORR/CRSurvivalReferenceR-GEMHigh grade B-NHL771%/29%median PFS and OS,(Wenger et al, 2005)(6478 years)10 and 11 months,R-GEMOXAggressive NHL4674%/72%2-yea

8、r EFS 43%,(El Gnaoui et al, 2007)2-year OS 66%R-GIFOX(Corazzelli et al, 2006)GaRD (Cabanillas et al, 2006) GaRDAggressive B-NHL2255%/27% (Smith et al, 2006)(CR/CRu)R + EDLBCL667%/50%(Leonard et al, 2005)R + EDLBCL1547%/33%median PFS 6 (Strauss et al, 2006)(CR/CRu) monthsR-CMDDLBCL3074%/57%2-year OS

9、45%, (Niitsu et al, 2006) (6579 years)(CR/CRu) PFS 37%R-TTPAggressive NHL71 (32 70% 25%median DR 21 (Younes et al, 2005)primaryprimary months refractory) refractoryR-TTPB-cell lymphoma1060%/30% (Canales et al, 2005)R-ADOXDLBCL (heavily 2070%/25%Median OS 11 mos Woehrer et al, 2005) pre-treated)Gisse

10、lbrecht C. B J H:2008 143, 607621CMD: irinotecan, mitoxantrone, dexamethasoneTTP: paclitaxel, topotecanE:epratuzumabAnother long list第20页/共64页第21页/共64页J of Clin Oncol,2005,23:2240-2247OS67 patients with recurrent B-NHL41 de novo DBLCL; 26 aggressive FL originRituximab提高提高ASCT疗效疗效Cumulative Proportio

11、n SurvivingP=0.004P=0.002Months Post-TransplantationMonths Post-TransplantationRituximab (n=67)NO rituximab (n=30)Rituximab (n=67)NO rituximab (n=30)第22页/共64页JOURNAL OF CLINICAL ONCOLOGYRPBPCcollectionR 1000mg/mRRd1d8BEAM + ASCTCYC第23页/共64页806040200总生存时间总生存时间100806040200生生存存率率% %MST 70月80例患者生存曲线80例患

12、者生存曲线1999-2004年,年,N=80, 5年生存率年生存率76中山大学肿瘤医院内科第24页/共64页黄慧强黄慧强等等癌症癌症2006,25(4):486489第25页/共64页第26页/共64页NNRR (%)RR (%)CR (%)CR (%)SD (%)SD (%)PD (%)PD (%)R-CHOPR-CHOP2 2505050505050R-EPOCHR-EPOCH181877.877.861.161.15.65.616.616.6R-DHAPR-DHAP7 785.785.771.471.414.314.3R-GEMOXR-GEMOX6 666.666.633.333.333

13、.333.3R-DHAOXR-DHAOXR-IMVP16 R-IMVP16 R-ICER-ICER-GDPR-GDPOtherOther5 59 911112 24 4606066.666.663.663.6100100100100606022.222.236.336.32525202011.111.19 9202022.222.227.327.3Total646473.473.445.345.312.512.514.114.1第27页/共64页第28页/共64页第29页/共64页 第30页/共64页第31页/共64页第32页/共64页Dense- RICER-ICENew molecules

14、DHAP.R-DHAPWhat Else?R- Other ASCT ASCT/PET-evaluation ASCT/ RIC alloOS benefitProlonging OS?更好的耐受性过去现在将来提高治愈机会(e.g. new anti CD 20, GA 101, CD40. anti-angiogenics lenalidomide)第33页/共64页第34页/共64页第35页/共64页McLaughlin J Clin Oncol 1998;16:2825331st relapsen =722nd relapsen =463rd relapsen =24ORR %01020

15、30604050574638Rituximab第36页/共64页CHOP every21 days(maximum 6 cycles)MabThera + CHOP every 21 days(maximum 6 cycles) ObservationMabThera maintenance*CRPR*375mg/m2 every 3 months for 2 years or until relapseRANDOMISATION MabThera maintenance in relapsed FL Study designRANDOMISATIONvan Oers M, et al. Bl

16、ood 2008; 112:Abstract 836.第37页/共64页MabThera maintenance in relapsed FL improved PFS after CHOP Rvan Oers M, et al. Blood 2008; 112:Abstract 836.PFS (%)After response toCHOP inductionp 0.000180604020010001234567p = 0.0438O N Number of patients at risk61 50 39 30 18 8349 7632 16 10 950262 69012345678

17、After response to MabThera-CHOP induction806040200100O N Number of patients at risk70 61 56 45 28 13 451 9164 47 37 29 21 10 165 98YearsMabTheraObservationMabTheraObservation第38页/共64页MabThera maintenance in relapsed FL improved PFS after CR/PRvan Oers M, et al. Blood 2008; 112:Abstract 836.100MabThe

18、raMedian 52.7 moObservationMedian 14.4 moAfter CR to MabThera plus CHOPp = 0.00380604020010001234567p = 0.00068O N Number of patients at risk30 16 13 1163038 4840 35 31 24 17 9229 49MabTheraMedian 41.8 moObservationMedian 15.6 mo012345678After non-CR to MabThera plus CHOP806040200O N Number of patie

19、nts at risk30 16 13 1163038 4840 35 31 24 17 9229 49PFS (%)Years第39页/共64页0.0010.1101000Vidal L, et al. J Natl Cancer Inst 2009; 101:248255.van Oers 2006Forstpointner 2006Ghielmini 2004 Hainsworth 2005 Hochster 2005 Hochster 2007Subtotal (95% CI)HR (95% CI)HR (95% CI)Weight (%)15.229.18.120.725.31.51

20、00p 0.00030.51 (0.310.86)0.49 (0.181.30)0.50 (0.270.92)0.86 (0.491.49)0.51 (0.251.04)4.51 (0.4743.4)0.60 (0.450.79) Favours MabThera maintenance Favours observationStudy1第40页/共64页2010 NCCN, FL第41页/共64页第42页/共64页第43页/共64页第44页/共64页随随机机化化R-FC q4wk 3FC q4wk 3再再分分期期R-FC q4wk 3FC q4wk 3SD 可以继续治疗可以继续治疗PD 推出

21、研究推出研究CR, PRl 复发复发/难治性难治性 CLLl 1次既往治疗次既往治疗l 全部全部Binet 分期分期l ECOG PS 01l 既往既往FC或美罗华治或美罗华治疗的病人排除疗的病人排除l n = 552招募期招募期: 20032007.Robak T, et al. Blood 2008; 112:Abstract LBA-1.第45页/共64页R-FCFCRobak T, et al. Blood 2008; 112:Abstract LBA-1.806040200100CR7058PR/nPR病人病人 (%)p = 0.00344645p = 0.86422413p = 0

22、.0007ORR第46页/共64页Robak T, et al. Blood 2008; 112:Abstract LBA-1.年年0.50.02.02.53.03.54.04.55.0PFS0.80.60.40.20.01.0p = 0.0002R-FC: 中位中位 30.6 月月FC: 中位中位 20.6 月月1.01.5第47页/共64页Fischer K, et al. Blood 2008; 112:Abstract 330.1563ORR = 77%(n = 62)病人病人 (%)806040200100所有病人所有病人PR/nPR71氟达拉滨氟达拉滨-敏感敏感氟达拉滨氟达拉滨-难

23、治性难治性未突变未突变IgVH11q del17p del78749244CRn = 41n = 9n = 39n = 13n = 9ORR第48页/共64页Percentage of patients8060402010057%36%ORR = 93%(n = 14)PR / nodular PRCR Rai stage IIIIV: 86% Median TTP: 15 months Median TTNT: 22 months Median survival: not reached at 40 monthsCastro JE, et al. Leukemia 2008; 22:2048

24、2053.第49页/共64页ResponseTotaln = 46RCn = 18RCCn = 28 ORR CR PR34 (74%)3 (7%)31 (67%)12 (67%)1 (6%)11 (61%)22 (78%)2 (7%)20 (71%)Robak T, et al. Eur J Haematol 2007; 79:107113.Median PFS 12 months (446)RC = rituximab + cladribineRCC = rituximab + cladribine + cyclophosphamide第50页/共64页第51页/共64页1. Umaa P, et al. Ann Oncol 2008; 19:Abstract 098.2. Umaa P, et al. Blood 2006; 108:Abstract 229.第52页/共64页B cellEffectorcellIncreased direct cell deathUnique type II epitope & elbow-hinge modificationIncreased ADCC Higher affinity to the ADCC receptor FcgRIIIALower CDC activityRecognition of type II epi

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论